Spero Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
675 Massachusetts Ave Ste 14, Cambridge,...Phone Number
(857) 242-1600Website
www.sperotherapeutics.comRevenue
$43 MillionStock Symbol
SPROIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Spero Therapeutics
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.Explore more
Spero Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spero Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Spero Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Spero Therapeutics
Click to see if Spero Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Spero Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Spero Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Spero Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Spero Therapeutics is spiking on competitors!
Check if Spero Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Spero Therapeutics
Compare insights from companies similar to Spero Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Spero Therapeutics
$43M
11-50
Public
$306.6M
2013
IC
Ian CritchleyVice President, Head of Clinical Microbiology
Company Profile Activity
Activity Insights
Spero Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Spero Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Spero Therapeutics.
Spero Therapeutics financials insights
Gather financial insights about Spero Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$33M
2016
Series B
$30M
2017
Series C
$51.7M
Grant
$6.8M
2018
Grant
$54.2M
2019
Grant
$5.9M
2021
Debt
$125M
Spero Therapeutics Tech Stack
A closer look at the technologies used by Spero Therapeutics
See more technologies
Most Recent Scoops
Earnings
reported no revenue for Q2 2026, compared with total revenue of $14.2 million for Q2 2025, with the decline primarily attributable to collaboration revenue from Pfizer and GSK having been fully realized in prior periods and all funding having been received under government awards.
Earnings, Accounting, Financial Reporting, Business Finance, Finance
Earnings
reported general and administrative expenses of $6.5 million for Q2 2026, compared to $5.9 million for Q2 2025, with the increase primarily driven by higher business development, legal, and consulting expenses.
Earnings, Business Development, Legal Affairs, Finance
Earnings
reported research and development expenses of $3.4 million for Q2 2026, compared to $10.7 million for Q2 2025, with the year-over-year decrease primarily driven by reduced clinical activity following the early completion of the Utebzi Phase III trial in H1 2025 and lower personnel-related costs.
Earnings, Research & Development, Clinical Operations, Finance
Earnings
reported a net loss of $9.6 million for Q2 2026, compared with a net loss of $1.7 million for Q2 2025, with diluted net loss per share of $0.16 for Q2 2026 versus $0.03 for Q2 2025.
Earnings, Finance
Earnings
Earnings, Finance
Spero Therapeutics News & Media
Spero Therapeutics Q2 Earnings Call Highlights
Spero Therapeutics (NASDAQ:SPRO) used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease. PresiSpero Therapeutics (SPRO) widens Q2 loss but lands $105M non-dilutive financing
Spero reported Q2 2026 net loss of $9.6M with no revenue, gained FDA approval for Utebzi, advanced SP001 in immunology, and closed a $105M non-recourse, non-dilutive royalty financing.Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that on July 22, 2026, the Compensation Committee of Spero’s Board of Directors approved a grant, to be made on August 3rd, of an aggregate of 324,622 stock options and 162,311 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 201
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spero Therapeutics
Sign Up For FreeTo access detailed company insights
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.... Read More
